期刊
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
卷 31, 期 4, 页码 396-400出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.beha.2018.09.013
关键词
Acute myeloid leukemia; AML; Assay; MFC; Multi-parameter flow cytometry; Minimal/measurable residual disease; MRD; Next-generation sequencing; NGS; Reverse-transcriptase-polymerase-chain reaction; RT-PCR
类别
Interest in detecting minimal/measurable residual disease (MRD) in acute myeloid leukemia (AML) has been increasing, but numerous issues need to be addressed if MRD assessment is to be routinely incorporated into practice. Assays, their reliability, standardization, and availability all must be considered, and a strategy developed to eradicate residual leukemia. This paper reviews some issues surrounding the routine incorporation of MRD assessment into practice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据